TRex Bio, Inc.
- Last sale
- Nov 12, 2026 · -1.91%
- Market cap
- $405.63M
- 28.79M shares
- Filings
- 40
—
—
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026−68.0% FY25 yoy
- $405.63M
- —
- —
- —
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Biological products, except diagnostic substances
TRex Bio, Inc. is the 67th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
VALNValneva SE———$499.8MJSPRJasper Therapeutics, Inc.———$445.9MTECXTectonic Therapeutic, Inc.———$436.1M
TRXBTRex Bio, Inc. (this company)———$405.6M
CCCCC4 Therapeutics, Inc.$35.9M1.0%292.1%$405.1MFENCFennec Pharmaceuticals Inc.$44.6M6.1%21.8%$381.4MALECAlector, Inc.$21.0M79.1%679.2%$363.3MPROKProkidney Corp.$893.0K1,075.0%7,725.2%$347.7MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
TRex Bio, Inc. · CIK 2139097 · Engraved from SEC EDGAR